SAM-101 / XTL Biopharma - LARVOL DELTA

Sustained Intraocular Pressure Reduction and Favorable Safety Profile of Intracameral Barogenetic Gene Therapy in Non-Human Primates (ASGCT 2026) - "Animals were randomized into treatment groups (n=3 per group) and received a single intracameral injection in the right eye (100 µL; 2E11 vector genomes per eye) of either scAAV2-mCherry (vehicle control), Or scAAV2-MGP-SAM-101-mCherry (SAM)...The ffERG recordings showed no significant changes in a- or b-wave amplitudes, indicating preserved retinal function...Conclusion This non-human primate study demonstrates that a single intracameral administration of barogenetic SAM gene therapy is safe, well-tolerated, and capable of producing sustained IOP reduction without compromising ocular structure or function. These results support the continued translational development of SAM as a durable, adherence-independent gene therapy for glaucoma and provide a strong preclinical foundation for advancement into clinical trials."

Clinical • Gene therapy • CNS Disorders • Gene Therapies • Glaucoma • Hematological Disorders • Inflammation • Ocular Inflammation • Ophthalmology